Kyverna Therapeutics, Inc. Common Stock (KYTX)vsModerna Inc (MRNA)
KYTX
Kyverna Therapeutics, Inc. Common Stock
$7.13
+1.28%
HEALTHCARE · Cap: $430.43M
MRNA
Moderna Inc
$154.04
-2.55%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
KYTX leads profitability with a 0.0% profit margin vs -141.4%. KYTX earns a higher WallStSmart Score of 28/100 (F).
KYTX
Avoid28
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KYTX.
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$154.04
$19.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 9.1x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : KYTX
The strongest argument for KYTX centers on Debt/Equity, Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : KYTX
The primary concerns for KYTX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
KYTX profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
KYTX carries more volatility with a beta of 1.99 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
KYTX generates stronger free cash flow (-41M), providing more financial flexibility.
Bottom Line
KYTX scores higher overall (28/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kyverna Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health challenges. Employing its proprietary genetically engineered T-cell technology, Kyverna aims to enhance the functionality of the immune system, offering specialized cellular therapies designed to improve patient outcomes substantially. With its commitment to developing cutting-edge therapeutic solutions and its strategic positioning within the growing biopharmaceutical sector, the company presents an appealing opportunity for institutional investors interested in the transformative potential of immunotherapy.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?